データなし
データなし
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
Sonoma Pharmaceuticals Terminates Agreement With EMC Pharma After It Did Not Meet Minimum Purchase Requirements
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
Sonoma Pharmaceuticals Announces The FDA 510k Review Panel Has Rated Its Microdacyn Hydrogel Substantially Equivalent For General & Plastic Surgery On November 8, 2024